Clinical Trial Update: Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking [NA]

View source ↗

Summary

Completed clinical trial assessing performance and safety of T4020 for corneal epithelial defect after epi-off accelerated crosslinking in keratoconus patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconus

Drugs mentioned

• T4020

Snippet

Sponsor: Laboratoires Thea | Conditions: Keratoconus | NA | Status: COMPLETED | Results posted: 2019-10-07